BRAF-activated long noncoding RNA modulates papillary thyroid carcinoma cell proliferation through regulating thyroid stimulating hormone receptor

Cancer Research and Treatment

Volumn 48, Issue 2, 2016, Pages 698-707

  Zheng, Haitao ^a   Wang, Meng ^a   Jiang, Lixin ^a   Chu, Haidi ^a   Hu, Jinchen ^a   Ning, Jinyao ^a   Li, Baoyuan ^a   Wang, Dong ^a   Xu, Jie ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

BRAF activated long noncoding RNA; Long noncoding RNA; Thyroid neoplasms

Indexed keywords

B RAF KINASE; BRAF ACTIVATED LONG NONCODING RNA; CYCLIN D1; LONG UNTRANSLATED RNA; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNTRANSLATED RNA; BRAF PROTEIN, HUMAN;

ARTICLE; CANCER SUSCEPTIBILITY; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; COMPARATIVE STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; PAPILLARY THYROID CARCINOMA CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; UPREGULATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PAPILLARY CARCINOMA; PATHOLOGY; THYROID TUMOR; TUMOR CELL LINE;

CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTORS, THYROTROPIN; RNA, LONG NONCODING; THYROID NEOPLASMS;

EID: 84963829487     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2015.118     Document Type: Article

References (25)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-7
2. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140: 317-22
3. Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu J, et al. BRAFactivated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 2014;8:1947-52
4. Fan M, Li X, Jiang W, Huang Y, Li J, Wang Z. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp Ther Med. 2013;5:1143-6
5. Yoon H, He H, Nagy R, Davuluri R, Suster S, Schoenberg D, et al. Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer. 2007;121:767-75
6. Caretti G, Di Padova M, Micales B, Lyons GE, Sartorelli V. The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev. 2004;18:2627-38
7. Borbone E, Troncone G, Ferraro A, Jasencakova Z, Stojic L, Esposito F, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas. J Clin Endocrinol Metab. 2011;96:1029-38
8. He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV, et al. Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab. 2015;100: E164-72
9. Bufalo NE, Dos Santos RB, Marcello MA, Piai RP, Secolin R, Romaldini JH, et al. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves' disease and Graves' ophthalmopathy. J Endocrinol Invest. 2015;38:555-61
10. Khan MS, Pandith AA, Masoodi SR, Wani KA, Ul Hussain M, Mudassar S. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status. Endocrine. 2014;47:449-55
11. Huth S, Jaeschke H, Schaarschmidt J, Paschke R. Controversial constitutive TSHR activity: patients, physiology, and in vitro characterization. Horm Metab Res. 2014;46:453-61
12. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc. 2006;1:2315-9
13. Telford WG, King LE, Fraker PJ. Rapid quantitation of apoptosis in pure and heterogeneous cell populations using flow cytometry. J Immunol Methods. 1994;172:1-16
14. Ngollo M, Lebert A, Dagdemir A, Judes G, Karsli-Ceppioglu S, Daures M, et al. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters. BMC Cancer. 2014;14:994
15. Esposito F, Tornincasa M, Pallante P, Federico A, Borbone E, Pierantoni GM, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab. 2012;97:E710-8
16. Dong C, Hemminki K. Modification of cancer risks in offspring by sibling and parental cancers from 2, 112, 616 nuclear families. Int J Cancer. 2001;92:144-50
17. Mattick JS. Non-coding RNAs: the architects of eukaryotic complexity. EMBO Rep. 2001;2:986-91
18. Brosnan CA, Voinnet O. The long and the short of noncoding RNAs. Curr Opin Cell Biol. 2009;21:416-25
19. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136:629-41
20. Jia H, Osak M, Bogu GK, Stanton LW, Johnson R, Lipovich L. Genome-wide computational identification and manual annotation of human long noncoding RNA genes. RNA. 2010;16: 1478-87
21. Flynn RA, Chang HY. Active chromatin and noncoding RNAs: an intimate relationship. Curr Opin Genet Dev. 2012;22:172-8
22. Kung JT, Colognori D, Lee JT. Long noncoding RNAs: past, present, and future. Genetics. 2013;193:651-69
23. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155-9
24. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008; 322:1695-9
25. Koh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo AM. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011;2:669-83